Why did seven out of nine clinically depressed patients with the R441H hTPH2 allele not respond to SSRIs?

Why did seven out of nine clinically depressed patients with the R441H hTPH2 allele not respond to SSRIs?

• A. They have a mutation in the postsynaptic serotonin receptor
• B. They do not release enough serotonin into the synapse
• C. They produce an enzyme that degrades SSRIs
• D. They have postsynaptic receptors that are always activated

Answer: (B)

The choice regarding the inability of seven out of nine clinically depressed patients with the R441H hTPH2 allele to respond to SSRIs is rooted in the role of the hTPH2 gene, which encodes for the enzyme tryptophan hydroxylase 2. This enzyme is crucial for the biosynthesis of serotonin, a key neurotransmitter involved in mood regulation. The R441H mutation in the hTPH2 allele is associated with disrupted serotonin production. An insufficient release of serotonin into the synaptic cleft can severely affect mood regulation and the overall efficacy of SSRIs, which function by inhibiting the reuptake of serotonin, thereby increasing its concentration and duration of action in the synaptic space. If these patients do not produce enough serotonin to begin with, SSRIs have less substrate to act upon, which explains the lack of response in these individuals. The other choices hint at mechanisms involving receptor function or degradation of medications, but they do not directly address the core issue of serotonin synthesis as affected by the R441H mutation. Thus, the lack of sufficient serotonin being released into the synapse is fundamentally why these patients did not respond to SSRIs.

The choice regarding the inability of seven out of nine clinically depressed patients with the R441H hTPH2 allele to respond to SSRIs is rooted in the role of the hTPH2 gene, which encodes for the enzyme tryptophan hydroxylase 2. This enzyme is crucial for the biosynthesis of serotonin, a key neurotransmitter involved in mood regulation.

The R441H mutation in the hTPH2 allele is associated with disrupted serotonin production. An insufficient release of serotonin into the synaptic cleft can severely affect mood regulation and the overall efficacy of SSRIs, which function by inhibiting the reuptake of serotonin, thereby increasing its concentration and duration of action in the synaptic space. If these patients do not produce enough serotonin to begin with, SSRIs have less substrate to act upon, which explains the lack of response in these individuals.

The other choices hint at mechanisms involving receptor function or degradation of medications, but they do not directly address the core issue of serotonin synthesis as affected by the R441H mutation. Thus, the lack of sufficient serotonin being released into the synapse is fundamentally why these patients did not respond to SSRIs.